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Serum laminin P1 in small cell lung cancer: a valuable indicator of distant
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Third Department ofInternal Medicine, Hyogo College ofMedicine, Nishinomiya, Hyogo 663, Japan.
Summary Serum laminin P1 was studied in patients with small cell lung cancer (SCLC), non-small cell lung
cancer (NSCLC), respiratory infections, pulmonary fibrosis, and in normal subjects. The level of serum
laminin P1 was elevated (> 1.27 U ml-') in 58.9% of SCLC and in 11.5% of NSCLC patients. Median value
in SCLC was significantly higher than that in NSCLC (P<0.01), respiratory infection (P<0.01), and in
normal subjects (P<0.01), but not statistically different from that in pulmonary fibrosis. The levels of serum
laminin P1 in SCLC were related to therapeutic response. However, no certain correlation was established
between the level of laminin P1 and the clinical stage of SCLC.
Laminin is a major non-collagenous glycoprotein found in
basement membranes. It has a cross-shaped structure and
can be degraded by protease into several fragments. Laminin
P1 is one such fragment and is chemically a pepsin-resistant
soluble peptide with a molecular weight of about 200000
DA. A sensitive radioimmunoassay for the laminin P1 frag-
ment has been developed (Risteli et al., 1981), and it has
been shown that laminin has complete cross-reactivity with
its pepsin-resistant fragment P1 (Rohde et al., 1979, 1980).
Laminin plays a significant role in the adhesion of cells to
basement membranes and extracellular matrix and in metas-
tatic capability of tumour cells (Hunt, 1989). It has been
demonstrated that human carcinoma cells bind laminin with
high affinity laminin receptors on the cell surface, and that
injection of the tumour cells preincubated with laminin into
animals resulted in both their increased retention in the lung
as well as enhanced metastases formation (Terranova et al.,
1982; Barsky et al., 1984). In addition, incubation of tumour
cells with antibody to laminin prior to injection markedly
reduced the number of metastases (Terranova et al., 1982).
Thus, laminin is believed to be involved in the metastatic
mechanism. Small cell lung cancer (SCLC) is characterised by
rapid proliferation and early metastatic dissemination among
the various histological types of lung cancer. Recently, a
proteinase capable of digesting laminin has been isolated and
characterised from the cytosol of human SCLC cells (Zucker
et al., 1988), and it has been reported that variant type of
SCLC cell lines synthesise laminin (Scarpa et al., 1988).
These reports led us to study the hypothesis that SCLC
may be associated with elevated laminin P1 levels by pro-
duction of laminin or increased degradation of basement
membrane utilising an endogenous proteinase. We hoped to
investigate whether laminin P1 could be a valuable indicator
of distal metastasis and thus be clinically useful as a bio-
marker.
Methods
Seventeen patients with newly diagnosed SCLC, 26 patients
with newly diagnosed non-small cell lung cancer (NSCLC)
(14 adenocarcinomas, eight squamous cell carcinomas, four
large cell carcinomas), 11 patients with respiratory infections,
seven patients with pulmonary fibrosis, and ten age-matched
normal subjects were included in this study (Table I). The
patients were seen consecutively at the Third Department of
Internal Medicine, Hyogo College Hospital from 1988 to
1991. A diagnosis of bronchogenic carcinoma was established
histologically by studying tumour specimens obtained by
bronchoscopy or percutaneous needle biopsy and/or sputum
cytology. A diagnosis of pulmonary fibrosis was made on the
basis of pulmonary function tests, chest X-ray films and
histological findings of transbronchial lung biopsy specimens.
Clinically the patients with pulmonary fibrosis were in a
stable state.
The patients with bronchogenic carcinoma were staged
prior to treatment according to the clinical criteria (Japan
Lung Cancer Society, 1987). Limited disease (LD) of SCLC
was defined as tumour confined to one hemithorax, with or
without ipsilateral mediastinal or supraclavicular lymph node
involvement. Patients with disease beyond these sites were
classified as extensive disease (ED). Response to chemother-
apy was assessed according to standard criteria. A complete
response (CR) was defined as total clinical and radio-
graphical resolution of disease for at least 4 weeks: a partial
response (PR) required at least a 50% reduction in the sum
of the product of the perpendicular diameters of all measur-
able lesions or a 50% or greater reduction in all evaluable
lesions. Anything less than a PR was judged as no change
(NC).
Blood samples of SCLC were obtained before and after
chemotherapy. Sera from inpatients with respiratory infection
were obtained from acutely ill individuals. The samples were
immediately placed on ice, centrifuged and the serum separ-
ated, after which each sample was stored at - 70°C until
assay.
Laminin P1 in serum was measured by the use of a
radioimmunoassay kit (Hoechst AG, Germany), and neuron
specific enolase (NSE, Shionogi, Osaka, Japan) and CEA
(Daiichi Radioisotope Laboratories, Tokyo, Japan) were also
measured with commercially available kits. Intra-assay
coefficients of variation (CV) for laminin P1 assay in normal
and pathological sera were 4.4% and 2.5%, while interassay
CVs were 4.9% and 6.1%, respectively. The statistical
significance of the results was determined by the
Mann-Whitney U test and linear regression analysis. A P
value of less than 0.05 was considered significant. Group
distributions were expressed as the median and mean ± s.d.
Results
The levels of serum laminin P1 before treatment are shown in
Table I. As can be seen, these levels were significantly higher
in SCLC compared with NSCLC, respiratory infection and
with normal subjects. The levels of laminin P1 in pulmonary
fibrosis were significantly higher than those in respiratory
infection, normal subjects and in NSCLC. However, there
was no significant difference in the level between SCLC and
pulmonary fibrosis.
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Table 1 Concentration of serum laminin P1 before treatment
Laminin P1 value (Uml-1)
Disease Mean ± s.d. (median)
Bronchogenic carcinoma (n = 43) 1.23 ± 0.43 (1.13)
Small cell lung cancer (n = 17) 1.43 ± 0.47 (1.44)*
non-small cell lung cancer (n = 26) 1.09 ± 0.34 (1.05)
adenocarcinoma (n = 14) 1.01 ± 0.20 (0.99)
squamous cell carcinoma (n = 8) 1.20 ± 0.51 (1.14)
large cell carcinoma (n = 4) 1.10 ± 0.40 (1.31)
Respiratory infection (n = 11) 0.98 ± 0.14 (1.01)
Pulmonary fibrosis (n = 7) 1.42 ± 0.23 (1.33)*
Normal subjects (n = 10) 1.03 ± 0.24 (1.02)
*Significantly higher than non-small cell lung cancer(P<0.01), respiratory
infection (P<0.01), and normal subjects (P<0.01).
The cut-off value of serum laminin P1 for 90% specificity
of the normal control subjects was found to be 1.27 U ml-.
None of the patients with respiratory infection showed a
laminin P1 level exceeding the cut-off value, whose laminin
P1 level was 0.98 ± 0.14 U ml-'. Laminin P1 levels above the
cut-off value were observed in three patients with NSCLC
(one adenocarcinoma, one large cell carcinoma, one squa-
mous cell carcinoma). Two out of these NSCLC patients
showed coexistence with pulmonary fibrosis roentgenologi-
cally. In accordance with the information provided by our
institution, the cut-off values of NSE and CEA are 10.0
ng ml-' and 5.0 ng ml', respectively. Table II shows the
positivity rate for laminin P1, NSE, and CEA at the cut-off
values. In the patients with SCLC, the positivity rate of
laminin P1 was 58.9%, while that in patients with NSCLC
was low (11.5%). Among the age-matched normal subjects,
the laminin PI assays were positive in one out of ten (10%),
yielding a diagnostic accuracy of 70.4%. The positivity rates
of NSE and CEA in SCLC were 88.2% and 35.3%, respec-
tively. In two SCLC patients with negative NSE, one had
positive laminin P1 level. There was no significant correlation
among the levels of serum laminin P1, NSE, and CEA in
patients with SCLC (Figures 1 and 2).
There was no significant difference in the level of laminin
P1 between the limited and extensive SCLC. However, the
level of NSE in extensive SCLC was significantly higher than
that in limited SCLC (P<0.05, Table III). The mean lam-
inin P1 level of limited SCLC was 1.51 ± 0.41 U ml-'
(mean ± s.d.), that for one or two sites of metastasis was
1.35 ± 0.37 U ml', and that for three or more metastatic
sites was 1.42 ± 0.61 U ml-'. Thus serum laminin P1 levels
did not tend to correlate with extent of disease (Figure 3).
The level of laminin P1 in limited SCLC was significantly
higher than that in stage 1 and 2 NSCLC (P<0.05). The
level in extensive SCLC was also significantly higher than
that in stage 4 NSCLC (P<0.05, Figure 4).
Ten of the 17 patients with SCLC achieved a CR or PR
after combination chemotherapy. The changes in serum
laminin P1 and NSE level in these patients are illustrated in
Figure 5. The mean serum laminin P1 and NSE levels
decreased significantly after the response. In the patients
responding to the therapy, serum NSE declined in 6/8 (75%)
patients, while laminin P1 declined in 6/10 (60% patients).
On the other hand, there was no significant change in the
mean serum laminin P1 levels in non-responding SCLC.
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Figure 1 Relation between serum NSE levels and laminin P1
concentrations in patients with small cell lung cancer. The cor-
relation is not significant.
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Table II Positive rate ofserum laminin P1, NSE, and CEA in patients
with bronchogenic carcinoma
Histologic Laminin P1 * NSE* CEA*
type (Uml-') (ngml-') (ng ml-')
1.00,j
.
0
S
0
0
N.S.
0
Small cell lung 10/17 (58.9%) 15/17 (88.2%) 6/17 (35.3%)
cancer (n = 17)
Non-small cell lung 3/26 (11.5%) 4/24 (16.7%) 9/24 (37.5%)
cancer (n = 26)
*Cut-off value of laminin P1, NSE, and CEA is 1.27 U ml
,
10.0 ngml-', 5.0 ng ml ', respectively.
0 5.0 10.0 15.0
CEA (ng ml-')
Figure 2 Relation between serum CEA levels and laminin P1
concentrations in patients with small cell lung cancer. The cor-
relation is not significant.
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Table III Serum lamininP1, NSE, and CEA levels in patients with small
cell lung cancer according to clinical stage
Clinical stage Positive rate Value (Uml-')
Laminin P1 LD 4/5 (80%) 1.51 ± 0.41 (1.45)-
(Uml-') ED 6/12 (50%) 1.39±0.51 (1.30)...
NSE LD 4/5 (80%) 19.0 7.8 (18.3)-p0
(ng ml-') ED 11/12 (92%) 72.3 96.7 (41.0)_20
CEA LD 0/5 2.9 1.3 (2.7)-p 007
(ngml-') ED 6/12 (50%) 6.2±4.6 (6.9) -
Values are expressed as mean ± s.d. (median). LD = limited disease;
ED = extensive disease.
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Figure 3 Serum laminin P1 levels in patients with small cell lung
cancer with respect to the number of metastatic sites.
The serial serum laminin P1 and NSE levels in a patient
with extensive SCLC are illustrated in Figure 6.
Discussion
In the present study, we found that the serum laminin P1
level in SCLC was significantly higher than that in NSCLC,
respiratory infections, and in normal subjects, and that
laminin P1 assay had a particularly high sensitivity for
SCLC. The provenance of the elevated levels of circulating
laminin in SCLC is unknown. However, it can be speculated
that the possible cause of the elevation is that SCLC cells
synthesise laminin in vivo. This possibility is supported by the
in vitro data of Scarpa et al. (1988) who have shown that
variant types of SCLC cell lines synthesise it.
Malignant tumour cells possess the abilities to invade sur-
rounding normal tissues and disseminate to form metastatic
foci at distant locations. In blood-borne tumour metastasis,
metastatic tumour cells must penetrate both the endothelial
cell layer and the underlying basement membrane. Tumour
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Figure 4 Comparison of serum laminin P1 levels between limited
small cell lung cancer and stage 1 or stage 2 non-small cell lung
cancer (P<0.05), and between extensive small cell lung cancer
and stage 4 non-small cell lung cancer (P<0.05).
invasion of the underlying basement membrane, penetration
and extravasation from blood vessels require type IV col-
lagenase and a proteinase capable of digesting laminin. Some
investigators have demonstrated production ofcollagenase by
some highly metastatic tumour cells (Salo et al., 1983; Trygg-
vason et al., 1987). Recently, a proteinase capable of diges-
ting laminin has been identified in SCLC cells in vitro
(Zucker et al., 1988).
Increases in the level of serum laminin P1 have been
reported under certain conditions. Bieglmayer et al. (1986)
described increases in the serum laminin P1 level in pregnant
women. In addition, increases have also been shown in
patients with diabetes mellitus (Hdgemann et al., 1986; Piets-
chmann et al., 1988), liver disease (Nouchi et al., 1987;
Roberts et al., 1989), progressive systemic sclerosis (Gerst-
meier et al., 1988), or in gynaecological cancer (Wurz &
Crombach, 1988). Increased lung collagen and collagen syn-
thesis have been demonstrated in several animal models of
pulmonary fibrosis (Greenberg et al., 1978; Snider et al.,
1978; Starcher et al., 1978; Last & Greenberg, 1980), and
conspicuous accumulation of laminin was found in the lung
interstitium of pulmonary fibrosis based on an
immunofluorescence study (Singer et al., 1986). In our
results, increased laminin P1 levels in serum were also dem-
onstrated in patients with pulmonary fibrosis.
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Figure 5 Change in serum laminin P1 and NSE levels in res-
ponders of small cell lung cancer before and after combination
chemotherapy. These two parameters significantly decreased after
the response.
In the present study, we attempted to determine whether
increased levels of circulating laminin correlate with the
presence of distal metastasis or the extent of the disease.
However, no significant difference in the level could be found
between the patient groups in clinical stages of SCLC. SCLC
is a rapidly proliferating neoplasm with a marked tendency
toward early metastatic spread. It has been shown that
laminin enhances metastases formation of tumour cells (Ter-
ranova et al., 1983; Barsky et al., 1984; Hunt, 1989). How-
ever, the value of serum laminin P1 for indicator of distal
metastasis in SCLC is disappointing.
We also investigated the possibility of the clinical useful-
ness of laminin P1 as a biomarker in bronchogenic car-
cinoma in comparison with CEA and NSE. Some tumour
marker levels often increase in inflammatory disease. How-
ever, in our results, none of the patients with respiratory
infection showed a serum laminin P1 level exceeding the
cut-off value. A preliminary study has demonstrated that
serum laminin P1 level exceeds the upper normal limit in
about 50% of tumour patients (Brocks et al., 1986). How-
ever, in the present study, the positivity rates of laminin P1
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Figure 6 Course of serum laminin P1, NSE, and CEA levels in a
limited-disease patient with small cell lung cancer. Laminin P1
and NSE levels fell after combination chemotherapy. With tu-
mour recurrence, laminin P1, NSE, and CEA levels increased. A
partial response was induced with salvage chemotherapy with
reduction in laminin P1 and NSE levels but CEA level showed a
further increase.
were low in NSCLC (11.5%). The positivity rate and diag-
nostic accuracy in SCLC were 58.9% and 70.4%, re-
spectively. In view of the sufficient diagnostic accuracy and
sensitivity observed in patients with SCLC, serum laminin P1
may be a useful tumour marker in differential diagnosis of a
suspected SCLC. It has been shown that serum NSE is a
highly specific marker for SCLC (Johnson et al., 1984;
Splinter et al., 1987). In our results, the positivity rate of
NSE in SCLC was 88.2%, while that for CEA in SCLC was
35.3%. Thus, laminin P1 assay in SCLC offers no superiority
in sensitivity over NSE assay, but is superior to CEA.
The present study showed no significant correlation among
the levels of serum laminin P1, NSE, and CEA in SCLC.
Furthermore, in two SCLC patients with negative NSE, one
had positive laminin P1 level. Therefore, these results imply
the possibility of a high degree of complementarity for a
combined tumour marker analysis.
Serial laminin P1 determination in SCLC was also per-
formed to investigate the potential usefulness of chemo-
therapeutic monitoring in comparison with NSE. The serum
laminin P1 level correlated to therapeutic response, showing
a decrease with remission and an increase with recurrence.
The results indicate that laminin P1 as well as NSE assay
may be useful for therapy monitoring.
We conclude that the sufficient sensitivity to SCLC and
specificity of laminin P1 warrants its clinical application as
one of the biomarkers in SCLC. However, serum laminin P1
will not help in assessing the occurrence of distal metastasis.
We could not verify any superiority of laminin P1 over NSE
assay as a marker for SCLC.
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